Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383336 | 0.81 | KDM4E (0.35) | ALDH1A1KDM4EMAPK1SMN1; SMN2HSD17B10 | |
| SCHEMBL383335 | 0.81 | KDM4E (0.35) | ALDH1A1KDM4EMAPK1SMN1; SMN2HSD17B10 | |
| SCHEMBL16897435 | 0.77 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPK1SMN1; SMN2KCNJ1 | |
| SCHEMBL4531684 | 0.75 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPK1SMN1; SMN2TRIM24 | |
| SCHEMBL29935900 | 0.75 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPK1SMN1; SMN2TRIM24 | |
| SCHEMBL8525606 | 0.74 | CYP11B1 (0.45) | ALDH1A1KDM4E | |
| SCHEMBL18664531 | 0.72 | KMT2A (0.42) | ALDH1A1KDM4EMAPK1SMN1; SMN2NPSR1 | |
| SCHEMBL20497363 | 0.72 | KMT2A (0.42) | ALDH1A1KDM4EMAPK1SMN1; SMN2NPSR1 | |
| SCHEMBL5187723 | 0.72 | KDM4E (0.59) | ALDH1A1KDM4EMAPK1SMN1; SMN2KCNJ1 | |
| SCHEMBL17085981 | 0.71 | FBP1 (0.59) | ALDH1A1MAPK1SMN1; SMN2NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3974426-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3349581-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3349581-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-108347942-B | Hepatitis B core protein modulators | 组装生物科学股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-20080176916-A1 | A-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| WO-2008019760-A1 | INSECTICIDAL ISOXAZOLINES | BAYER CROPSCIENCE AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| US-7291634-B2 | α-amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | disclosed |
| US-20060270719-A1 | 2-[(Cyclopropylmethoxy-benzenesulfonyl)-(4-[1,2,3]triazol-2-yl-benzyl)-amino]-N-hydroxy-acetamide; selective inhibitors of matrix-degrading metalloproteinases, especially MT1-MMP, MMP-2 and MMP-9; Osteoporosis; Antitumor, antiproliferative agents | NOVARTIS AG (CH) | 2006-11-30 | — | — | US | disclosed |
| US-7112611-B2 | 1g(α)-amino-N-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| US-20040082630-A1 | 1g(a)-Amino-n-hydroxy-acetamide derivatives | NOVARTIS AG (CH) | 2004-04-29 | — | — | US | disclosed |
| EP-1360175-A1 | 1G(A)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | Novartis AG (CH) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002064552-A1 | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2002-08-22 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270719-A1 | 2-[(Cyclopropylmethoxy-benzenesulfonyl)-(4-[1,2,3]triazol-2-yl-benzyl)-amino]-N-hydroxy-acetamide; selective inhibitors of matrix-degrading metalloproteinases, especially MT1-MMP, MMP-2 and MMP-9; Osteoporosis; Antitumor, antiproliferative agents | MMP9, MMP14, MMP13 | ALDH1A1 678/4885KDM4E 1051/4885MAPK1 807/4885 |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | ALDH1A1 4382/4885KDM4E 1741/4885MAPK1 3138/4885 |
| US-20080176916-A1 | A-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | MMP1, MMP9, MMP14 | ALDH1A1 149/4885KDM4E 1381/4885MAPK1 2146/4885 |
| US-20040082630-A1 | 1g(a)-Amino-n-hydroxy-acetamide derivatives | MMP1, MMP9, MMP13 | ALDH1A1 85/4885KDM4E 961/4885MAPK1 1545/4885 |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | ALDH1A1 4382/4885KDM4E 1741/4885MAPK1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.